Ascletis Pharma Valuation

Is 1672 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1672 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1672's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1672's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1672?

Other financial metrics that can be useful for relative valuation.

1672 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does 1672's PB Ratio compare to its peers?

The above table shows the PB ratio for 1672 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average10.6x
2137 Brii Biosciences
0.3x-7.4%HK$1.1b
2496 Wuhan YZY Biopharma
24.7xn/aHK$1.3b
6978 Immunotech Biopharm
16xn/aHK$1.4b
2898 Sunho Biologics
1.3xn/aHK$789.5m
1672 Ascletis Pharma
0.6x12.0%HK$1.4b

Price-To-Book vs Peers: 1672 is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (10.6x).


Price to Earnings Ratio vs Industry

How does 1672's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.7%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.7%
n/an/an/a
No more companies

Price-To-Book vs Industry: 1672 is good value based on its Price-To-Book Ratio (0.6x) compared to the Hong Kong Biotechs industry average (2.5x).


Price to Book Ratio vs Fair Ratio

What is 1672's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1672 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1672's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1672 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$1.37
HK$2.91
+112.7%
32.0%HK$3.85HK$1.98n/a2
Sep ’25HK$0.85
HK$2.97
+249.3%
27.2%HK$3.78HK$2.16n/a2
Aug ’25HK$1.09
HK$2.97
+172.4%
27.2%HK$3.78HK$2.16n/a2
Jul ’25HK$0.80
HK$2.98
+272.1%
27.7%HK$3.80HK$2.15n/a2
Jun ’25HK$1.21
HK$2.98
+146.0%
27.7%HK$3.80HK$2.15n/a2
May ’25HK$1.30
HK$2.98
+129.0%
27.7%HK$3.80HK$2.15n/a2
Apr ’25HK$1.43
HK$2.97
+108.0%
27.4%HK$3.79HK$2.16n/a2
Mar ’25HK$1.72
HK$3.02
+75.4%
25.6%HK$3.79HK$2.25n/a2
Feb ’25HK$1.75
HK$3.02
+72.4%
25.6%HK$3.79HK$2.25n/a2
Jan ’25HK$1.46
HK$2.85
+95.2%
35.4%HK$3.86HK$1.84n/a2
Dec ’24HK$1.85
HK$2.82
+52.5%
34.6%HK$3.80HK$1.84n/a2
Nov ’24HK$1.86
HK$2.82
+51.7%
34.6%HK$3.80HK$1.84n/a2
Oct ’24HK$1.97
HK$2.82
+43.2%
34.6%HK$3.80HK$1.84HK$1.142
Sep ’24HK$2.20
HK$2.82
+28.3%
34.6%HK$3.80HK$1.84HK$0.852
Aug ’24HK$1.96
HK$1.98
+1.1%
6.0%HK$2.10HK$1.86HK$1.092
Jul ’24HK$1.88
HK$1.91
+1.8%
3.5%HK$1.98HK$1.85HK$0.802
Jun ’24HK$1.88
HK$3.03
+61.1%
48.3%HK$5.09HK$1.90HK$1.213
May ’24HK$2.54
HK$3.03
+19.3%
48.3%HK$5.09HK$1.90HK$1.303
Apr ’24HK$2.50
HK$3.03
+21.2%
48.3%HK$5.09HK$1.90HK$1.433
Mar ’24HK$3.30
HK$3.05
-7.5%
47.3%HK$5.09HK$1.90HK$1.723
Feb ’24HK$4.27
HK$3.17
-25.6%
40.8%HK$5.00HK$2.12HK$1.753
Jan ’24HK$4.74
HK$3.17
-33.0%
40.8%HK$5.00HK$2.12HK$1.463
Dec ’23HK$3.27
HK$2.92
-10.6%
36.4%HK$4.42HK$2.07HK$1.853
Nov ’23HK$2.60
HK$2.15
-17.1%
4.0%HK$2.24HK$2.07HK$1.862
Oct ’23HK$2.75
HK$2.29
-16.8%
0.6%HK$2.30HK$2.27HK$1.972

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies